Dr Agarwals Eye Hospital Ltd Stock Price Today (NSE: DRAGARWQ)

Dr Agarwals Eye Hospital Ltd

DRAGARWQHospital
5018.3082.30 (1.61%)
Market Closed

Fundamental Score

...

Dr Agarwals Eye Hospital Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Dr Agarwals Eye Hospital Ltd share price today is 5018.30, down 1.61% on NSE/BSE as of 2 June 2026. Dr Agarwals Eye Hospital Ltd (DRAGARWQ) is a Small-cap company in the Hospital sector with a market capitalisation of 2.78K (Cr). The 52-week high for DRAGARWQ share price is 6392.00 and the 52-week low is 4142.00. At a P/E ratio of 44.20x, DRAGARWQ is currently trading below its industry average P/E of 52.84x. The company has a Return on Equity (ROE) of 29.50% and a debt-to-equity ratio of 1.06.

Dr Agarwals Eye Hospital Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
5740.00
Low
4795.00
Volume
294.09090909090907
Change
+3.19%

Dr Agarwals Eye Hospital Ltd share price chart: 3.19% return over the past month. 52-week high ₹6392.00, 52-week low ₹4142.00.

Dr Agarwals Eye Hospital Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
5124.005169.205105.905110.0019.00 (Cr)
4999.905145.004894.455119.2060.00 (Cr)
5101.155101.154935.004983.9598.00 (Cr)
5106.155200.005084.505150.75210.00 (Cr)
5178.905740.004811.105087.451.24K (Cr)
5128.405200.005000.005159.05313.00 (Cr)
5112.155136.855084.455121.0544.00 (Cr)
4795.005117.754795.005093.95171.00 (Cr)
5100.055139.605040.005073.35115.00 (Cr)
5070.005170.405050.005082.80369.00 (Cr)

Dr Agarwals Eye Hospital Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
4983.955740.004795.005110.00+2.53%
4879.955200.004612.504983.95+2.13%
4460.004990.004425.004699.55+5.37%
4626.004950.004498.404599.95-0.56%
5340.056392.004412.054650.20-12.92%
5772.005840.005099.005334.35-7.58%
5384.105890.005013.155735.30+6.52%
4820.005650.004750.005235.70+8.62%
4490.004880.004350.004859.10+8.22%
4360.005449.004231.004472.55+2.58%
4522.004780.004280.004381.90-3.10%
4411.554562.004142.004522.20+2.51%

AI Research Briefing

Powered by Gemini · 2026-04-10

Overvalued small-cap riding a growth narrative with substantial execution risk; liquidity a concern.

Research Confidence
6.0/10Moderate
COMPOUNDERConsolidation - CMP is -23.7% from 52W highExpensive - P/E 44.2x vs industry P/E 52.84x

WHAT'S HAPPENING NOW (last 2-4 weeks)

Dr. Agarwal's Health Care submitted its quarterly compliance certificate for Q4 FY26 on April 6, 2026.

CORE STORY (THE REAL GAME)

Dr. Agarwal's is riding the wave of increased demand for specialized eye care in India and internationally, expanding aggressively through new facilities and potential acquisitions. This is a growth story, not a value play.

Why Now
  • Strong Q3 FY26 results with 23% YoY revenue growth
  • Aggressive expansion with 38 new facilities in 9 months
  • 74.3% YoY PAT growth for 9M'FY26
Potential Catalysts
  • Successful integration of new facilities
  • Acquisition of smaller players in key markets
  • Faster-than-expected growth in international markets
Key Risks
  • Small-cap liquidity risk
  • High promoter pledge (29.26%)
  • Stretched valuation (P/E 44.2x vs. industry 52.84x)
Institutional Activity

FII increased stake by 0.25%, DII increased stake by 0.05%, Promoter increased stake by 0.77%.

Macro Context

Healthcare sector faces potential cost increases due to geopolitical instability (Iran War impact).

Cash Flow Quality

Profit converting to cash - Free Cash Flow 5Y: ₹43.95 Cr

3–6 Month Outlook

Expect continued growth driven by expansion. Key is managing costs and integrating new facilities. 3-6 month horizon: Monitor expansion progress and profitability.

Primary Thesis Risk

Inability to sustain high growth rates and manage expansion costs will lead to a derating.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Excellent

Return on Equity (ROE)

29.50%

Profit generated per ₹1 of shareholder equity

Good

Return on Capital (ROCE)

17.53%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

28.53%

Average operating profit margin over 5 years

Dividend Yield

0.10%

Annual dividend as % of current share price

Dr Agarwals Eye Hospital Ltd Valuation Check

Good

Price to Earnings (P/E)

44.20x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

52.84x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

72.67%

% shares held by company founders/management

Poor

FII Holding

1.74%

% shares held by foreign institutional investors

Poor

DII Holding

2.36%

% held by domestic mutual funds, LIC, banks

Poor

Promoter Pledged %

29.26%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

36.54%

Net profit growth vs same quarter last year

Average

Revenue Growth (Quarterly YoY)

15.20%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

17.68%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

32.05%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

32.05%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

1.06x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

6.58x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

43.95 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Dr Agarwals Eye Hospital Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of DRAGARWQ across key market metrics for learning purposes.

Positive Indicators

11 factors identified

Strong Return on Equity (29.50%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (17.53%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (28.53%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Robust Profit Growth (36.54%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (15.20%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (17.68% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (32.05% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (32.05% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Strong Interest Coverage (6.58x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹43.95 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (72.67%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Risk Factors

4 factors identified

Premium Valuation Risk (P/E: 44.20x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Elevated Debt Levels (D/E: 1.06)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.

Limited Institutional Interest (FII+DII: 4.10%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

High Share Pledging Risk (29.26%)

Observation: Significant promoter share pledging creates potential overhang.

Analysis: High pledging levels may create selling pressure during market downturns.

Dr Agarwals Eye Hospital Ltd vs Hospital Peers

Peer Comparison - Hospital

Compare Dr Agarwals Eye Hospital Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
52.8/100
5018
₹2783.13
44.2
Average
29.50%
Excellent
17.53%
Good
1.1
Average
32.05%
Excellent
17.68%
Excellent
0.10%
69.1/100
1069
₹109416.28
77.7
Average
12.72%
Average
14.88%
Average
0.3
Excellent
80.50%
Excellent
46.01%
Excellent
0.13%
50.2/100
8273
₹104825.94
62.7
Average
18.42%
Good
16.64%
Good
0.9
Good
33.72%
Excellent
14.15%
Good
0.26%
55.6/100
961
₹68301.24
67.8
Average
10.13%
Average
11.96%
Average
0.3
Excellent
70.31%
Excellent
10.93%
Good
0.11%
62.2/100
1884
₹39051.19
45.9
Average
24.22%
Excellent
20.75%
Excellent
0.6
Good
43.49%
Excellent
11.88%
Good
0.24%
15.4/100
741
₹34688.15
94.5
Average
8.26%
Poor
10.68%
Average
0.5
Excellent
-7.24%
Poor
-13.71%
Poor
0.75%
61/100
1240
₹33498.00
56.0
Average
16.48%
Good
19.74%
Good
0.3
Excellent
70.15%
Excellent
19.73%
Excellent
0.04%
45.1/100
741
₹27605.54
84.0
Average
18.48%
Good
15.00%
Good
1.4
Average
25.01%
Excellent
22.01%
Excellent
0.00%
51.2/100
480
₹16844.04
145.2
Average
4.76%
Poor
9.99%
Poor
0.5
Good
41.72%
Excellent
26.38%
Excellent
0.00%
54.6/100
1351
₹13410.38
52.8
Average
17.43%
Good
18.69%
Good
0.5
Good
33.66%
Excellent
16.08%
Excellent
0.23%
36.4/100
647
₹10474.40
296.2
Average
5.14%
Poor
8.56%
Poor
1.9
Average
19.34%
Excellent
15.22%
Excellent
0.00%

Dr Agarwals Eye Hospital Ltd PE Ratio History

Historical price-to-earnings ratio for DRAGARWQ — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 2025116.28₹5334.3545.9x
FY 202498.64₹6147.1062.3x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Dr Agarwals Eye Hospital Ltd Dividend History

Annual cash dividends paid by DRAGARWQ — dividend yield 0.10%

Financial YearDividends Paid (₹ Cr)
FY 20252.35 Cr
FY 20242.58 Cr
FY 20231.41 Cr
FY 20220.02 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Dr Agarwals Eye Hospital Ltd Quarterly Performance

Latest quarterly metrics for DRAGARWQ — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

15.20%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

36.54%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

17.68%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

32.05%

Compounded annual net profit growth over 5 years

Dr Agarwals Eye Hospital Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for DRAGARWQ — calculated from daily price history

53RSI 14
Neutral — RSI 53

Momentum is balanced — neither overbought nor oversold.

SMA 50
4918
▲ Price above SMA 50 — Short-term bullish
SMA 200
4945
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
1K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Dr Agarwals Eye Hospital Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Dr Agarwals Eye Hospital Ltd (DRAGARWQ) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Dr Agarwals Eye Hospital Ltd

About DRAGARWQ (Dr Agarwals Eye Hospital Ltd)

Dr. Agarwals Eye Hospital Ltd is a prominent healthcare institution dedicated to preserving and restoring vision across a wide geographical expanse. Beyond the familiar walls of tr...aditional hospitals, it functions as a network of specialized eye care centers, each a beacon of hope for individuals struggling with visual impairments. The hospital distinguishes itself by combining cutting-edge medical technology with the expertise of a dedicated team of ophthalmologists, surgeons, and support staff. Their commitment extends to every aspect of eye health, from comprehensive diagnostics to intricate surgical procedures, creating a holistic approach that prioritizes patient well-being. This institution stands as a testament to innovation in the realm of ophthalmology, continually pushing the boundaries of what is possible in visual care. The hospital's comprehensive suite of services addresses a spectrum of ocular conditions, catering to both common ailments and complex disorders. They offer advanced treatments for prevalent issues such as cataracts and refractive errors, allowing patients to regain clear sight. In addition, Dr. Agarwals Eye Hospital provides specialized care for more intricate conditions like glaucoma, retinal diseases, and corneal disorders. The hospital uses modern methods to correct the position of the eye and make sure it looks right. Whether it's a routine check-up or a demanding surgical intervention, the focus remains unwavering: to provide personalized treatment plans that cater to the unique needs of each patient. Through their commitment to individualized care, the hospital aims to enhance not only vision but also the overall quality of life. Dr. Agarwals Eye Hospital has made a commitment to worldwide access to quality eye care, therefore, they have geographically diverse practices that demonstrate the organization's broad vision. The business provides a full array of services, bringing excellent eye care to diverse communities in India as well as countries in Africa and the Indian Ocean. Each facility is designed to satisfy the particular requirements of the surrounding region, ensuring that people can obtain top-notch eye care regardless of where they are. By broadening their scope, Dr. Agarwals Eye Hospital solidifies its role as a global leader in ophthalmology, transforming lives and strengthening communities by means of vision.

Company Details

Symbol:DRAGARWQ
Industry:Hospital
Sector:Hospital

Key Leadership

Dr. Amar Agarwal F.R.C.Ophth, F.R.C.S, M.S., MBBS
Founder, Chairman & MD
Dr. Athiya Agarwal D.O., F.R.S.H(Lon)
Founder & Whole Time Director
Mr. Yashwanth Venkat
Interim Chief Financial Officer

DRAGARWQ Share Price: Frequently Asked Questions

What is the current share price of Dr Agarwals Eye Hospital Ltd?

Dr Agarwals Eye Hospital Ltd (DRAGARWQ) trades at ₹5018.30 on NSE and BSE. Market cap ₹2.78K (Cr). Educational data only.

What is the P/E ratio of Dr Agarwals Eye Hospital Ltd?

Dr Agarwals Eye Hospital Ltd has a P/E of 44.20x vs industry average 52.84x.

What is the Bull Run score for Dr Agarwals Eye Hospital Ltd?

Dr Agarwals Eye Hospital Ltd has a Bull Run score of 52.8/100 based on 25+ financial parameters.

Does Dr Agarwals Eye Hospital Ltd pay dividends?

Dr Agarwals Eye Hospital Ltd has a dividend yield of 0.10%. Past dividends don't guarantee future payments.

What is the ROE of Dr Agarwals Eye Hospital Ltd?

Dr Agarwals Eye Hospital Ltd has ROE of 29.50%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Dr Agarwals Eye Hospital Ltd?

Dr Agarwals Eye Hospital Ltd has debt-to-equity of 1.06.

Is Dr Agarwals Eye Hospital Ltd a good investment?

Bull Run gives Dr Agarwals Eye Hospital Ltd a score of 52.8/100. This is not investment advice — consult a SEBI-registered advisor.